Investing in the development and characterization of nanoparticle libraries to support drug delivery

What is the Nanoparticle program?

Verily has a robust nanoparticle R&D program that features a scalable platform for synthesis, characterization and high-throughput screening of particles with predictable physicochemical properties. 

How are you making it happen?

Our program is focused on lipid-based nanoparticles (LNPs and liposomes), the most widely used nanocarriers for drug delivery. LNPs are flexible, allowing for attachment of targeting groups such as antibodies or peptides to their surface, and amenable to a diversity of payloads, including nucleic acids. When properly designed, LNPs can deliver their therapeutic payload into a cell, which requires it to fuse with the cell membrane, and avoids cell degradation. 

As part of this program, we’ve developed an automated high throughput platform that allows for synthesis of nanoparticle libraries using a combinatorial chemistry approach. In addition to this high throughput in vitro screening, we’ve developed a proprietary method of "barcoding" unique particle formulations to conduct in vivo studies in what we anticipate will be a faster and more efficient manner. 

By gathering all of this information on the chemistry, the physical characteristics, in vitro assay results and in vivo study results, we are building a data analysis pipeline to more efficiently design and synthesize particles in the future.